Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03602885 · ClinicalTrials.gov registry record · NA
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
A NA study of Metastatic Colorectal Cancer and Metastatic Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 5
- Study locations
NCT03602885: Completed NA study of Metastatic Colorectal Cancer and Metastatic Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03602885 is a NA study of Metastatic Colorectal Cancer and Metastatic Pancreatic Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 186-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03602885, a NA study of Metastatic Colorectal Cancer and Metastatic Pancreatic Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 5
- Study locations
Study Summary
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers. In this study Latinos who are considering 1st line chemotherapy for newly diagnosed advanced colorectal or pancreatic cancer will be randomized to usual care or to usual care supplemented by a Spanish/English language multimedia chemotherapy educational intervention. Primary informal caregivers will also be invited to participate. This research study is evaluating if a new set of educational materials will improve the treatment decision-making process for Latinos with advanced gastrointestinal cancers. This research study will involve about 154 patients and 154 caregivers.
Primary Outcome
Participants were asked how likely they thought chemotherapy was to cure their cancer (response options: very likely, somewhat likely, a little likely, not at all likely, don't know). Not at all likely is considered accurate, all other responses are considered inaccurate.
Conditions Studied
Interventions
- BEHAVIORAL Usual chemotherapy education (CE)
- BEHAVIORAL Chemotherapy education intervention (CEI)
Study Locations (5)
Massachusetts
- Boston Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Florida
- Moffitt Cancer Center - Tampa
New Mexico
- University of New Mexico Cancer Center - Albuquerque
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2020-11-27 |
| Phase | NA |
What the finished NCT03602885 record still lists
NCT03602885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 186-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual chemotherapy education (CE) is the first listed.
NCT03602885 lists 5 locations in 4 states (Massachusetts, Florida, New Mexico).
Frequently Asked Questions
What is clinical trial NCT03602885 about?
NCT03602885 is a clinical study titled "EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options". The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers. In this study Latinos who are considering 1st line chemotherapy for newly diagnosed advanced colorectal or pancreatic cancer will be randomized to usual care or to u...
What is the current status of trial NCT03602885?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2018-09-01. Estimated completion is 2020-11-27.
What conditions does trial NCT03602885 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer.
What interventions are being tested in trial NCT03602885?
The interventions under investigation include: Usual chemotherapy education (CE) (BEHAVIORAL), Chemotherapy education intervention (CEI) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03602885?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03602885 being conducted?
This trial has 5 study locations across Florida, Massachusetts, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03602885's enrollment target sits among peer trials
10 45th of 45 higher than 1 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
RECRUITING · NA
-
Pressure-enabled Delivery in Radioembolization (TriNav Study)
ACTIVE NOT RECRUITING · NA
-
Improving Informed Consent for Palliative Chemotherapy
COMPLETED · NA
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI